# Sharekhan

by BNP PARIBAS

# Sector: IT & ITES Result Update

	Change
Reco: <b>Buy</b>	$\leftrightarrow$
CMP: <b>Rs. 623</b>	
Price Target: <b>Rs. 750</b>	<b>^</b>
↑ Upgrade ↔ No change	<b>↓</b> Downgrade


## Company details

Market cap:	Rs. 169,184 cr
52-week high/low:	Rs. 652/375
NSE volume: (No of shares)	20.4 lakh
BSE code:	532281
NSE code:	HCLTECH
Sharekhan code:	HCLTECH
Free float: (No of shares)	54.3 cr

## Shareholding (%)

Promoters	60.3
FII	25.6
DII	10.1
Others	4.0

## **Price chart**



#### **Price performance**

(%)	1m	3m	6m	12m			
Absolute	8.3	36.9	5.1	22.4			
Relative to Sensex	-1.8	20.0	17.0	27.5			
Sharekhan Research, Bloomberg							

## **HCL Technologies**

## Good quarter, strong deal wins

HCL Tech reported largely in-line revenue performance, while EBIT margin and net profit beat our estimates. Constant currency (CC) revenue declined 7.2% q-o-q, broadly in-line with our estimates, owing to supply-side constraints due to COVID-19 (1/3rd of total revenue impact from COVID) and reduction of revenue from offshoring of a large deal. IT and business services (down 7.8% q-o-q CC) and engineering R&D (down 9% q-o-q CC) were the key drags on revenues owing to exposure to troubled verticals and asset heavy industries. EBIT margin contracted 36bps q-o-q to 20.5%, beating our estimates, owing to increased amortisation due to its investments (-67bps), higher R&D expenditure (-12bps), revenue decline (-70bps), partially offset by benefits from rupee depreciation (+76bps) and reduction in travel expenses (+40bps). Net profit of Rs. 2,923 crore (down 7.3% q-o-q) was 8.6% ahead of our estimates aided by higher profitability and higher other income (includes sale of land parcel of \$14.4 million). The management also highlighted that COVID-19 related impact on the demand side stabilized after initial impact of ramp-downs, volume reduction and discounts to some customers in the stressed sectors. Hence, the management provided its guidance on revenue growth in the range of 1.5% -2.5% q-o-q for the remaining quarters of FY2021. This guidance translates to -3.3% to -0.8% growth in FY2021. On margin front, management expects EBIT margin to be in the range of 19.5-20.5% for FY2021 (EBIT margin was at 19.6% in FY2020). HCL Tech impressed with flow of large deal wins, strong FCF generation and strong margin defense.

## **Key positives**

- Strong order bookings and healthy deal pipeline (up 40% y-o-y); secured vendor consolidation deal
- HCL software revenue has been progressing well as per earlier guidance
- Free Cash Flow (FCF) at \$757 mn with FCF to net income conversion at 196%.

#### **Key negatives**

- ERD revenue declined 9% q-o-q CC
- Mode-3 margin contracted 70bps q-o-q

### Our Call

Valuation – Maintain Buy with revised PT of Rs. 750: We have revised our earnings estimates upward for FY2021E/FY2022E, to factor in better-than-expected margin performance in Q1FY2021 and commentary on stabilization of demand-side impact owing to COVID-19. Strong order flows and vendor consolidation would help the company return to a sequential positive growth trajectory. Robust demand for managed services on cloud platforms and emergence of new business models for deeply impacted verticals would create opportunities for the company. At CMP, the stock trades at 15x/14x of its FY2021E/FY2022E earnings. The company has impressed with consistent wins of large deals, strong FCF generation and good margin defense. We maintain our Buy rating on the stock with a revised PT of Rs. 750.

#### **Key Risks**

Any integration issues in ongoing M&A activities especially IP-related transactions could impact earnings. Further, high dependence on IMS could create challenges to its revenue growth trajectory.

Valuation					Rs cr
Particulars	FY18	FY19	FY20	FY21E	FY22E
Revenue	50,570.0	60,427.0	70,678.0	73,005.0	78,869.3
OPM (%)	22.6	23.1	23.6	24.8	24.4
Adjusted PAT	8,780.0	10,123.0	11,061.0	11,308.9	12,217.4
% YoY growth	3.8	15.3	9.3	2.2	8.0
Adjusted EPS (Rs.)	31.3	36.8	40.8	41.7	45.0
P/E (x)	19.9	16.9	15.3	15.0	13.8
P/B (x)	2.4	2.1	3.3	3.0	2.7
EV/EBITDA (x)	7.3	5.9	5.0	4.6	4.3
RoNW (%)	25.3	26.0	23.8	20.9	20.4
RoCE (%)	30.0	29.2	25.3	22.8	22.4

Source: Company; Sharekhan Research



Revenue in-line, margins beat estimates: HCL Tech reported largely in-line revenue performance, while EBIT margin and net profit beat our estimates. Constant currency (CC) revenue declined 7.2% q-o-q, broadly in-line with our estimates, owing to supply-side constraints due to COVID-19 (1/3rd of total revenue impact from COVID) and reduction of revenue from offshoring of a large deal. Mode-1 and Mode-3 services revenue declined 9.5% and 1.6% in CC terms, respectively, Mode-2 service revenues declined by 1.6% q-o-q. USD revenues declined 7.4% q-o-q to \$2,355.5 million during the quarter. EBIT margin contracted 36bps q-o-q to 20.5%, beating our estimates, led by rupee tailwinds, cost management, right shoring, automation and a change in the mix of business. The margin headwinds were increased depreciation and amortization owing to its investments (-67bps), R&D expenditure (-12bps), revenue decline (-70bps), which was partially offset by benefits from rupee depreciation (+76bps) and reduction in travel expenses (+40bps). Net profit of Rs. 2,923 crore (down 7.3% q-o-q) was 8.6% ahead of our estimates aided by higher profitability and higher other income (includes sale of land parcel of \$14.4 million).

Reinstated guidance, expect positive q-o-q growth for the remaining quarters of FY2021: Management indicated that the business impact due to COVID-19 has remained lower compared to what was anticipated at the beginning of the year. Hence, the management provided its guidance on revenue growth in the range of 1.5% - 2.5% q-o-q for the remaining quarters of FY2021. This guidance translates to negative 3.3% to negative 0.8% growth in FY2021. On the margin front, the management expects EBIT margin to be in the range of 19.5-20.5% for FY2021 (EBIT margin was at 19.6% in FY2020). Management remains confident on sequential growth for the remaining quarters of FY2021 on the back of strong deal wins, healthy deal pipeline, traction for infra business (cloud migration projects), higher demand for HCL software products with limited impact from COVID-19 and increasing spending on digital transformation works. Management sees stability in lifesciences and healthcare, financial service, technology and telecom verticals, which performed quite well during Q1FY2021. Management also highlighted that COVID-19 related impact on the demand side stabilized after the initial impact of ramp-downs, volume reduction and discounts to some customers in the stressed sectors.

## Q1FY2021 Result key highlights from earnings call

- Reinstated guidance: Management highlighted that resilience in operating model, portfolio mix, and relationship with customers beyond contract helped the company ride through this pandemic. It expects revenue to increase q-o-q by an average of 1.5%-2.5% in CC for the next 3 quarters, implies a revenue decline of -3.3% to -0.8% for FY2021. The management believes that the growth for the remaining quarters of FY2021 would be supported by strong order bookings and a healthy deal pipeline. Management expects EBIT margin to be in the range of 19.5%-20.5% for FY2021 as against EBIT margin of 19.6% in FY2020.
- IT and business services revenue declined 7.8% on CC owing to significant revenue decline from the directly impacted verticals such as manufacturing, retail, travel, hospitality and media. Lifesciences and healthcare, financial service, technology and telecom performed quite well during the quarter.
- Engineering and R&D services revenue declined 9% q-o-q on CC, owing to significant revenue loss from directly impacted segments like aerospace, automobiles and office automation. The revenue decline also includes the revenue decline from the offshoring of large deals during the quarter.
- **Deal Bookings in IT and business services and ERD services** were healthy. This provides revenue growth visibility for the remaining period of the year.
- Products and Platform revenue A decline of 2.1% CC was less compared to IT and business unit and ERD services. Over the last 12 months, HCL Tech completed over 16,500 sales transactions across 11,000 unique customers and onboarded more than 2,400 partners and reseller. The company released new products across portfolio. HCL Tech added 250+ new customers during last one year including 100+ in last quarter alone. The transition remains on track. COVID-19 impact has been very limited in this P&P segment, supported by building relationships beyond contract with customers, diversification across industries and geographies and new demand ecommerce, digital experience and security. Management remains cautiously optimistic for the P&P business segment. Over the last three quarters, the run-rate of incremental revenue in P&P business is around 600 million on CC basis. This is tracking well with the company's earlier guidance of \$625 million first 12 months.



- **IMS business:** The management indicated that higher adoption of cloud is a tailwind for its infrastructure business. Enterprises are looking cloud adoption, digital infrastructure including cyber security, network management, automation led operation model, which would create good opportunities for HCL Tech.
- Strong deal closures: The deal closures have been decent in Q1FY2021. HCL Tech signed 11 new transformational deals, led by key industry verticals including telecommunication, financial services, manufacturing, life sciences and healthcare. The company's bookings TCV (net new deals) is higher on y-o-y basis and the renewals were also robust during the quarter. The company won a large consolidation opportunity in Europe and the revenue from this opportunity will ramp-up gradually over next few quarters.
- HCL Tech expanded its preferred services partnership with Broadcom Inc., broadening its professional services offerings to include Symantec Enterprise Division (SED) consulting services.
- Strong deal pipeline: HCL Tech's management indicated that the deal pipeline has increased 40% q-o-q during the quarter. Management sees a healthy deal pipeline in lifesciences, financial services, technology, energy and auto segments. Two broad themes such as (1) momentum in cost transformation and vendor consolidation deal (especially in energy and auto) and (2) acceleration in digital transformation (cloud, digital work place and cyber security) are playing out. The management witnessed a good deal creation activity in existing clients, which will create opportunities for the company.

Results					Rs cr
Particulars	Q1FY21	Q1FY20	Q4FY20	y-o-y (%)	q-o-q (%)
Revenue (\$ mn)	2,355.5	2,363.6	2,543.4	-0.3	-7.4
Net sales	17,841.0	16,425.0	18,590.0	8.6	-4.0
Direct costs	10,728.0	10,631.0	11,151.0	0.9	-3.8
Gross profit	7,113.0	5,794.0	7,439.0	22.8	-4.4
SG&A	2,205.0	2,105.0	2,391.0	4.8	-7.8
EBITDA	4,908.0	3,689.0	5,048.0	33.0	-2.8
Depreciation and amortisation	906.0	595.0	839.0	52.3	8.0
EBIT	4,002.0	3,094.0	4,209.0	29.3	-4.9
Forex gain/(loss)	0.0	19.0	-36.0	-	-
Other income	205.0	109.0	23.0	88.1	791.3
PBT	4,207.0	3,222.0	4,196.0	30.6	0.3
Tax provision	929.0	705.0	707.0	31.8	31.4
Net profit	2,923.0	2,220.0	3,153.0	31.7	-7.3
EPS (Rs.)	10.8	8.2	11.6	31.7	-7.3
Margin (%)				BPS	BPS
EBITDA	27.5	22.5	27.2	505	36
EBIT	22.4	18.8	22.6	359	-21
NPM	16.4	13.5	17.0	287	-58

Source: Company; Sharekhan Research



## **Operating metrics**

Particulars	Revenues	Contribution	\$ Grow	th (%)	CC gro	wth (%)
Particulars	(\$ mn)	(%)	q-o-q	у-о-у	q-o-q	y-o-y
Revenues (\$ mn)	2,356	100	-7.4	-0.3	-7.2	1.0
Geographic mix						
Americas	1,500	63.7	-6.9	-6.2	-6.9	-5.8
Europe	667	28.3	-8.7	8.9	-8.5	11.4
RoW	188	8.0	-5.0	26.5	-5.1	31.2
Industry verticals						
Financial services	528	22.4	-1.7	10.0	-1.7	11.7
Manufacturing	426	18.1	-19.0	-9.4	-18.8	-8.3
Technology & services	405	17.2	-1.7	-9.3	-1.2	-8.8
Retail & CPG	236	10.0	-9.2	4.9	-9.0	6.7
Telecommunications, media,	108	27.7	-4.4	9.5	-4.1	10.6
publishing & entertainment	179	7.6	-15.2	-5.3	-15.5	-4.4
Lifesciences & healthcare	323	13.7	1.5	6.7	1.9	7.1
Public services	259	11.0	-8.2	4.4	-7.1	7.0
Service line						
IT and business services	1,654	70.2	-7.9	0.0	-7.8	-5.6
Engineering and R&D Services	377	16.0	-9.1	0.0	-9.0	-5.1
Products & platforms	325	13.8	-2.4	0.0	-2.1	77.7
Clients Contribution						
Top 5	327	13.9	-14.7	-16.6	-	-
Top 10	492	20.9	-12.0	-12.9	-	_
Top 20	725	30.8	-11.1	-10.3	-	-


Source: Company; Sharekhan Research

## Strong EBIT margin defense



Source: Company, Sharekhan Research

## Product & platform revenue (\$ mn) & margin (%)



Source: Company, Sharekhan Research




#### **Outlook**

Gartner estimates IT services spending would decline around 6.8% worldwide in 2020 due to COVID-led business disruption. However, the management highlighted that COVID-19 related impact on the demand side stabilized after initial impact of ramp-downs, volume reduction and discounts to some customers in the stressed sectors given its large deal wins, healthy deal pipeline and limited impact on its P&P business. HCL Tech has invested aggressively in the fast-growing Mode-2 (a good proxy for digital offering) capabilities, which would help HCL Technologies to match the industry's growth. Further, the company has made large investments towards the acquisition of IP products to diversify its focus on new high-margin revenue streams. The addressable market opportunity for information management services (IMS) is huge with only 10-12% penetration of addressable market. Given its differentiated positioning in IMS and strong capabilities in engineering services, HCL Technologies is well positioned to maintain growth momentum in these segments going ahead.

#### **Valuation**

**Maintain Buy with revised PT of Rs. 750:** We have revised our earnings estimates upward for FY2021E/FY2022E, to factor in better-than-expected margin performance in Q1FY2021 and commentary on stabilization of demand-side impact owing to COVID-19. Strong order flows and vendor consolidation would help the company to return to sequential positive growth trajectory. Robust demand for managed services on cloud platforms and emergence of new business models for deeply impacted verticals would create opportunities for the company. At CMP, the stock trades at 15x/14x of its FY2021E/FY2022E earnings. The company has impressed with consistent wins of large deals, strong FCF generation and good margin defense. We maintain our Buy rating on the stock with a revised PT of Rs. 750.

## One-year forward P/E (x) band



Source: Sharekhan Research

### Peer comparison

	СМР	O/S	MCAP -	P/E	P/E (x) EV/EBIDTA (x)		P/B	V (x)	RoE	(%)	
Particulars	(Rs / Share)	Shares (Cr)	(Rs Cr)	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Infosys	904	424	385,028	22.6	20.3	14.8	13.3	3.2	3.1	25.9	28.5
Wipro	262	570	149,433	16.3	14.9	4.5	3.9	2.6	2.4	13.9	14.0
TCS	2,201	375	826,031	27.5	24.3	20.1	18.1	10.0	9.7	35.9	40.6
HCL Tech	623	271	169,183	15.0	13.8	4.6	4.3	3.0	2.7	20.9	20.4

Source: Company, Sharekhan Research



## **About company**

HCL Tech is a leading global technology company providing software-led IT solutions, remote infrastructure management, and BPO services and engineering-related services. Further, the company helps global enterprises re-imagine and transform their businesses through digital technology transformation. HCL Tech leverages its global network of integrated co-innovation labs and global delivery capabilities to provide holistic multi-service delivery in key industry verticals.

#### Investment theme

HCL Tech's revenue growth momentum is expected to accelerate, led by several large deal wins in the past few quarters and gradual recovery in infrastructure management services. The company focuses on chasing large deals to capture market share from incumbents in consolidation deals. Being the leader in IMS practices and the third-largest engineering services player globally in revenue, the company is well positioned to win large deal wins. Strong deal wins along with acquisition of select IP products will help the company to drive growth going ahead.

## **Key Risks**

1) Continued slowdown in organic revenue growth, 2) integration issues in ongoing M&A activities, especially IP-related transactions, 3) rupee appreciation and/or adverse cross-currency movements, 4) pressure in renewal of IMS deals, 5) any hostile regulatory visa norms could have an impact on employee expenses, and 6) any major macro issues in developed markets, especially in the U.S. and Europe.

### **Additional Data**

Key management personnel

3 3 1	
Shiv Nadar	Founder & Chairman
C Vijay Kumar	President & CEO
Prateek Aggarwal	Chief Financial Officer
G H Rao	President – Engineering and R&D Services
Rahul Singh	President – Financial Services

Source: Company Website

#### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Vanguard Group Inc/The	1.49
2	Artisan Partners LP	1.48
3	BlackRock Inc	1.39
4	SBI Funds Management Pvt Ltd	1.30
5	Life Insurance Corp of India	1.11
6	ICICI Prudential Asset Management	1.08
7	Vontobel Holding AG	0.97
8	Virtus Investment Partners Inc	0.95
9	Nomura Holdings Inc	0.87
10	Lazard Limited	0.65

Source: Bloombera

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.



Know more about our products and services

## For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.